Relapse in common lymphoma subtypes: Salvage treatment options for follicular lymphoma, diffuse large cell lymphoma and Hodgkin disease

British Journal of Haematology

Volumn 133, Issue 1, 2006, Pages 3-18

  Seyfarth, Bärbel ^a   Josting, Andreas ^b   Dreyling, Martin ^c   Schmitz, Norbert ^d  

^a Westpfalz Klinikum GmbH   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d DEPARTMENT OF CARDIOLOGY   (Germany)

Author keywords

Autologous and allogeneic transplantation; Monoclonal antibodies; Radioimmunotherapy; Relapsed lymphoma; Salvage chemotherapy

Indexed keywords

ALEMTUZUMAB; ALKYLATING AGENT; ANTHRAQUINONE; BENDAMUSTINE; CARBOPLATIN; CARMUSTINE; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GEMCITABINE; IBRITUMOMAB TIUXETAN; IFOSFAMIDE; MELPHALAN; METHYLPREDNISOLONE; MITOXANTRONE; MONOCLONAL ANTIBODY; OXALIPLATIN; PREDNISONE; PROCARBAZINE; PURINE DERIVATIVE; RITUXIMAB; TOSITUMOMAB I 131; UNINDEXED DRUG; VINCRISTINE; VINCRISTINE SULFATE;

ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOLOGOUS BONE MARROW TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RELAPSE; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; DRUG CYTOTOXICITY; DRUG MEGADOSE; FOLLICULAR LYMPHOMA; GRAFT VERSUS LYMPHOMA EFFECT; HEALTH CARE POLICY; HODGKIN DISEASE; HUMAN; IMMUNE DEFICIENCY; KAPLAN MEIER METHOD; LARGE CELL LYMPHOMA; MULTIVARIATE ANALYSIS; NEPHROTOXICITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; REVIEW; SALVAGE THERAPY; SCORING SYSTEM; UNSPECIFIED SIDE EFFECT;

HODGKIN DISEASE; HUMANS; LYMPHOMA; LYMPHOMA, FOLLICULAR; LYMPHOMA, LARGE-CELL, DIFFUSE; RADIOIMMUNOTHERAPY; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT FAILURE;

EID: 33644687850     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2006.05975.x     Document Type: Review

References (119)

1. Anderson J.E. Litzow M.R. Appelbaum F.R. 1993 Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience Journal of Clinical Oncology 11 2342 2350
2. Ardeshna K.M. Smith P. Norton A. Hancock B.W. Haskin P.J. Mac Lennon K.A. Marcus R.E. Jelliffe A. Vaughan G. Hudson G.V. Linch D.C. 2003 Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial Lancet 362 516 522
3. Armitage J.O. Biermann P.J. Vose J.M. 1991 Autologous bone marrow transplantation for patients with relapsed Hodgkin's disease American Journal of Medicine 91 605 610
4. Attal M. Socie G. Molina L. 1997 Allogeneic bone marrow transplantation for refractory or recurrent follicular lymphoma: a case-matched analysis with autologous transplantation from the French bone marrow transplant group registry data Blood 93 1120a
5. Baetz T. Belch A. Couban S. 2003 Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical trials Group Annals of Oncology 14 1762 1767
6. Biermann P.J. Bagin R.G. Jagannath S. 1993 High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: long term follow-up in 128 patients Annals of Oncology 4 767 773
7. Blay J. Gomez F. Sebban C. Bachelo T. Biron P. Guglielmi C. Hagenbeek A. Somers R. Chauvin F. Philip T. 1998 The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group Blood 92 3562 3568
8. Bonfante V. Santoro A. Viviani S. 1997 Outcome of patients with Hodgkin's disease failing after primary MOPP/ABVD Journal of Clinical Oncology 15 528 534
9. Bosch F. Perales M. Cobo F. 1997 Fludarabine, cyclophosphamide and mitoxantrone (FCM) therapy in resistant or relapsed chronic lymphocytic leukemia or follicular lymphoma (abstract) Blood 90 2360
10. Brice P. Bastion Y. Lepage E. Brousse N. Haioun C. Moreau P. Straetmans N. Tilly H. Tabah I. Solal-Celigny P. 1997 Comparison in low-tumour-burdon follicular lympomas between initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etudes des Lymphomes de l'Adulte Journal of Clinical Oncology 15 1110 1117
11. Cabanillas F. Hagemeister F. Bodey G. 1982 An effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy Blood 60 693 697
12. Cabanillas F. Hagemeister F. Mc Laughlin P. 1987 Results of MIME salvage regimen for recurrent or refractory lymphoma Journal of Clinical Oncology 5 407 412
13. Chao N. Rosenberg S. Horning S. 1990 CEPP(B): an effective and well-tolerated regimen in poor risk, aggressive non Hodgkin's lymphoma Blood 76 1293 1298
14. Chau I. Webe A. Cunningham D. Hill M. Rao S. Ageli S. Norman A. Gill K. Howard A. Catovsky D. 2001 An oxaliplatin-based chemotherapy in patients with relapsed or refractory intermediate and high-grade non-Hodgkin's lymphoma British Journal of Haematology 115 786 792
15. Coiffier B. Haioun C. Ketterer N. Engert A. Tilly H. Ma D. 1998 Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study Blood 92 1927 1932
16. Coiffier B. Lepage E. Briere J. Herbrecht R. Tilly H. Bouabdallah R. 2002 CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma New England Journal of Medicine 346 235 242
17. Colwill R. Crump M. Couture F. Danish R. Stewart A.K. Sutton D.M. Scott J.G. Sutcliffe S.B. Brandwein J.M. Keating A. 1995 Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation Journal of Clinical Oncology 13 396 402
18. Crump M. Baetz T. Couban S. Belch A. 2004 Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma Cancer 101 1835 1842
19. Davis T. Levy R. White C.A. 1997 Retreatments with rituximab have significant efficacy, do not cause HAMA, and are a viable minimally toxic alternative in relapsed or refractory non-Hodgkin's lymphoma Blood 90 2269
20. De Lord C. Newland A. Linch D. 1992 Failure of IMVP-16 as second-line treatment for relapsed or refractory high-grade non-Hodgkin's lymphoma Hematological Oncology 10 81 86
21. Deconinck E. Foussard C. Milpied N. Bertrand P. Michenet P. Cornillet-LeFebvre P. Escoffre-Barbe M. Maisioneuve H. Delwail V. Gressin R. Legouffe E. Vilque J.P. Desablens B. Jaubert J. Ramee J.F. Jenabian A. Thyss A. Le Pourhiet-Le Mevel A. Travade P. Delepine R. Colombat P. 2005 High dose therapy followed by autologous purged stem cell transplantation and doxorubicin based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS Blood 105 3817 3823
22. Dhedin N. Giraudier S. Gaulard P. Esperou H. Ifrah N. Michallet M. 1999 Allogeneic bone marrow transplantation in aggressive non-Hodgkin's lymphoma (excluding Burkitt and lymphoblastic lymphoma): a series of 73 patients from the SFGM database. Societe Francaise de Greffe de Moelle British Journal of Haematology 107 154 161
23. Diehl V. Franklin J. Pfreundschuh M. Lathan B. Paulus U. Hasenclever D. Tesch H. Herrmann R. Dörken B. Müller-Hermelink H.K. Dühmke E. Löffler M. German Hodgkin's Lymphoma Study Group 2003 Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease New England Journal of Medicine 348 2386 2395
24. Dreger P. Glass B. Seyfarth B. Humpe A. Claviez A. von Neuhoff N. Suttorp M. Schoch R. Schmitz N. 2000 Reduced-intensity allogeneic stem cell transplantation as salvage treatment for patients with indolent lymphoma or CLL after failure of autologous SCT Bone Marrow Transplantation 26 1361 1362
25. El Gnaoui T. Dupuis J. Joly B. Behadj K. Rahmouni A. Copie-Bergmann C. Allain A. Tabah-Fish I. Reyes F. Haioun C. 2004 Rituximab, gemcitabine and oxaliplatin (R-GEMOX): a promising regimen for refractory/relapsed B-cell lymphoma Blood 104 2483 681a abstract number
26. Faulkner R.D. Craddock C. Byrne J.L. Mahendrea P. Haynes A.P. Prentice H.G. Potter M. Pagliuca A. Ho A. Devereux S. McQuaker G. Mufti G. Yin J.L. Russell N.H. 2004 BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients Blood 103 428 434
27. Feuring-Buske M. Kneba M. Unterhalt M. Engert A. Gramatzki M. Hiller E. Trümper L. Brugger W. Ostermann H. Atzpodien J. Hallek M. Aulitzky E. Hiddemann W. 2000 IDEC-C2B8 (rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German low grade lymphoma Study Group Annals of Hematology 79 493 500
28. Fisher R. De V.V. Hubbard S. 1979 Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse Annals of Internal Medicine 90 761 776
29. Foran J.M. Rohatiner A.Z. Cunningham D. Popescu R.A. Solal-Celigny P. Ghielmini M. Coiffier B. Johnson P. Gisselbrecht C. Reyes F. Radford J. Bessell E. Souleau B. Benzohra A. Lister A. 2000 European phase-II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma and small B-cell lymphocytic lymphoma Journal of Clinical Oncology 18 317 324
30. Forstpointner R. Dreyling M. Repp R. Hermann S. Hänel A. Metzner B. Pott C. Hartmann F. Rothmann F. Rohrberg R. Böck H.P. Wandt H. Unterhalt M. Hiddemann W. 2004 The addition of rituximab to a combination of fludarabine, cyclophosphamide and mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared to FCM alone in patients with relapsed or refractory follicular and mantle cell lymphomas - results of a prospective randomized study of the German low grade lymphoma Study Group (GLSG) Blood 104 3064 3071
31. Friedberg J.W. Neuberg D. Stone R.M. Alyea E. Jallow H. LaCasce A. Mauch P. Gribben J.G. Ritz J. Nadler L.M. Soiffer R. Freedman A.S. 1999 Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma Journal of Clinical Oncology 17 3128 3135
32. Fung H. Forman S. Nademanee A. 2003 A new preparative regimen for older patients with aggressive CD 20-positive B-cell lymphoma utilizing standard-dose yttrium-90 ibritumomab tiuxetan (Zevalin) radioimmunotherapy (RIT) combined with high-dose BEAM followed by autologous hematopoietic cell transplantation (AHCT): targeted intensification without increased transplant-related toxicity Blood 102 248a
33. Gajewski J.L. Philips G.L. Sobocinski K.A. 1996 Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease Journal of Clinical Oncology 14 572 578
34. Girouard C. Dufresne J. Imrie K. Stewart A.K. Brandwein J. Prince H.M. 1997 Salvage chemotherapy with mini-BEAM for relapsed or refractory non-Hodgkin's lymphoma prior to autologous bone marrow transplantation Annals of Oncology 8 675 680
35. Glass B. Nickelsen M. Dreger P. Claviez A. Hasenkamp J. Wulf G. Trümper L. Schmitz N. 2004 Reduced-intensity conditioning prior to allogeneic transplantation of hematopoietic stem cells: the need for T cells early after transplantation to induce a graft-versus-lymphoma effect Bone Marrow Transplantation 34 391 397
36. Gordan L.N. Grow W.B. Pusateri A. Douglas V. Mendenhall N.P. Lynch J.W. 2005 Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders Journal of Clinical Oncology 23 1096 1102
37. Gordon L.I. Molina A. Witzig T. Emmanouilides C. Raubtischek A. Darif M. 2004 Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study Blood 103 4429 4431
38. Gribben J.G. Freedman A.S. Neuberg D. Ray D.C. Blake K.W. Woo S.D. Grossbard M.L. Rabinowe S.N. Coral F. Freeman G.J. 1991 Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell-lymphoma New England Journal of Medicine 325 1525 1533
39. Guglielmi C. Gomez F. Philip T. Hagenbeek A. Martelli M. Sebban C. 1998 Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial Journal of Clinical Oncology 16 3264 3269
40. Hainsworth J.D. Litchy S. Shaffer D.W. Lackey V.L. Grimaldi M. Greco F.A. 2005 Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma - a randomized phase II trial of the Minnie Pearl Cancer Research Network Journal of Clinical Oncology 6 1088 1095
41. Hamlin P.A. Zelenetz A.D. Kewalramani T. Qin J. Satagopan J.M. Verbel D. Noy A. Portlock C. Straus D. Yahalom J. Nimer S. Moskowitz C. 2003 Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma Blood 102 1989 1996
42. Hiddemann W. Kneba M. Dreyling M. Schmitz N. Lengfelder E. Schmits R. Reiser M. Metzner B. Harder H. Hegewisch-Becker S. Fischer T. Kropff M. Reis H.E. Freund M. Wormann B. Fuchs R. Planker M. Schimke J. Eimermacher H. Trümper L. Alsaoud A. Parwaresch R. Unterhalt M. 2005 Front-line therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristin and prednisone (CHOP) significantly improves the outcome of patients with advanced stage follicular lymphomas as compared to CHOP alone - results of a prospective randomized study of the German low grade lymphoma Study Group (GLSG) Blood 106 3725 3732
43. Hoppe R. Kushlan P. Kaplan H. 1981 The treatment of advanced stage favourable histology non-Hodgkin's lymphoma: a preliminary report of a randomized trial comparing single agent chemotherapy, combination chemotherapy and whole body irradiation Blood 58 592 598
44. Horning S. 1993 Natural history of and therapy for the indolent non-Hodgkin's lymphomas Seminars in Oncology 20 75 88
45. Horning S. Rosenberg S. 1984 The natural history of initially untreated low-grade non-Hodgkin's lymphomas New England Journal of Medicine 311 1471 1475
46. Jaffe E.S. Harris N.L. Stein H. Vardiman J.W. (eds) 2001 World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of Hematopoietic and Lymphoid Tissues IARC Press Lyon
47. Jones R.J. Piantadosi S. Mann R.B. 1990 High-dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin's disease Journal of Clinical Oncology 8 527 537
48. Josting A. Katay I. Rueffer U. Winter S. Tesch H. Engert A. Diehl V. Wickramanayake P.D. 1998 Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dexa-BEAM) Annals of Oncology 9 289 296
49. Josting A. Rueffer U. Franklin J. Sieber M. Diehl V. Engert A. 2000 Prognostic factors and treatment outcome in primary progressive Hodgkin's lymphoma - a report from the German Hodgkin's Lymphoma Study Group (GHSG) Blood 96 1280 1286
50. Josting A. Franklin J. May M. Koch P. Beykirch M. Heinz J. Rudolph C. Diehl V. Engert A. 2002a A new prognostic score based on treatment outcome of patients with relapsed Hodgkin lymphoma registered in the database of the German Hodgkin Lymphoma Study Group (GHSG) Journal of Clinical Oncology 20 221 230
51. Josting A. Rudolph C. Reiser M. Mapara M. Sieber M. Kirchner H.H. Dorken B. Hossfeld D.K. Diehl V. Engert A. 2002b Time-intensified dexamethason/ cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed or refractory Hodgkin's diseases Annals of Oncology 10 1628 1635
52. Josting A. Rudolph C. Mapara M. Glossmann J.P. Sienawski M. Sieber M. Kirchner H. Dörken B. Hossfeld D. Kisro J. Metzner B. Berdel W. Diehl V. Engert A. 2005a Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma - results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG) Annals of Oncology 16 116 123
53. Josting A. Nogová L. Franklyn J. Glossmann J.P. Eich H.T. Sieber M. Schober T. Boettcher H.D. Schulz U. Müller R.P. Diehl V. Engert A. 2005b Salvage radiotherapy in patients with relapsed and refractory Hodgkin's Lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group Journal of Clinical Oncology 23 1522 1529
54. Kaminski M.S. Zelenetz A.D. Press O.W. Saleh M. Leonard J. Fehrenbacher L. Lister T.A. Stagg R. Tidmarsh G. Kroll S. Wahl R. Knox S. Vose J.M. 2001 Pivotal study of iodine 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphoma Journal of Clinical Oncology 19 3918 3928
55. Ketterer N. Salles G. Moullet I. Dumontet C. El-Jaafari-Corbin A. Tremisi P. Thieblemont C. Durand B. Neidhardt-Berard E.M. Samaha H. Rigal D. Coiffier B. 1998 Factors associated with successful mobilization of peripheral blood progenitor cells in 200 patients with lymphoid malignancies British Journal of Haematology 103 235 242
56. Kewalramani T. Zelenetz A. Nimer S. Portlock C. Straus D. Noy A. O'Connor O. Filippa D.A. Truya-Feldstein J. Gencarelli A. Qin J. Waxman A. Yaholom J. Moskowitz C.H. 2004 Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma Blood 103 3684 3688
57. Klasa R.J. Meyer R.M. Shustik C. Sawka C.A. Smith A. Guevin R. Maksymiuk A. Rubinger M. Samosh M. Laplante S. Grenier J.P. 2002 Randomized phase III study of fludarabine phosphate versus cyclophosphamide, vincristine and prednisone in patients with recurrent low-grade non-Hodgkin's lymphoma previously treated with an alkylating agent or alkylator-containing regimen Journal of Clinical Oncology 20 4649 4654
58. Koenigsmann M. Knauf W. Herold M. Pasold R. Müller G. Eschenburg H. Kahl C. Lankner V. Assmann M. Jentsch-Ullrich K. Mohren M. Bartsch R. Franke A. 2004 Fludarabine and bendamutine in refractory and relapsed indolent lymphoma - a multicenter phase I/II trial of the East German Society of Haematology and Oncology (OSHO) Leukemia & Lymphoma 45 1821 1827
59. Lazzarino M. Orlandi E. Montillo M. Tedeschi A. Pagnucco G. Astori C. 1999 Fludarabine, cyclophosphamide and dexamethasone (FluCyD) combination is effective in pretreated low-grade non-Hodgkin's lymphoma Annals of Oncology 10 59 64
60. Lenz G. Dreyling M. Schiegnitz E. Haferlach T. Hasford J. Unterhalt M. Hiddemann W. 2004a Moderate increase of secondary malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomised trial of the German Low Grade Study Group Journal of Clinical Oncology 22 4926 4933
61. Lenz G. Dreyling M. Schiegnitz E. Forstpointner R. Wandt H. Freund M. Hess G. Trümper L. Diehl V. Kropff M. Kneba M. Schmitz N. Metzner B. Pfirrmann M. Unterhalt M. Hiddemann W. 2004b Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma - results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG) Blood 104 2667 2674
62. Leonard J.P. Zelenetz A.D. Vose J.M. 2000 Iodine I 131 tositumomab for patients with low-grade or transformed low-grade NHL: complete response data Blood 96 728a
63. Linch D.C. Winfield D. Goldstone A.H. Moir D. Hancock B. McMillan A. Chopra R. Milligan D. Hudson G.V. 1993 Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial Lancet 341 1051 1054
64. Longo D. Duffey P. Young R. 1992 Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure Journal of Clinical Oncology 10 210 218
65. Maloney D.G. Grillo-Lopez A.J. White C.A. 1997 IDEC-C2B8 (Rituximab) anti CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma Blood 90 2188 2195
66. Marcus R. Imrie K. Cunningham D. Flores E. Catalano J. Solal-Celigny P. Offner F. Walewski J. Raposo J. Jack A. Smith P. 2005 CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma Blood 105 1417 1423
67. McLaughlin P. Hagemeister F.B. Romaguera J.E. 1996 Fludarabine, mitoxantrone and dexamethasone: an effective regimen for indolent lymphoma Journal of Clinical Oncology 14 1262 1268
68. McLaughlin P. Grillo-Lopez A. Link B. Levy R. Czuczman M.S. Williams M.E. Heyman M.R. Bence-Bruckler I. White C.A. Cabanillas F. Jain V. Ho A.D. Lister J. Wey K. Shen D. Dallaire B.K. 1998a Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a 4-dose treatment program Journal of Clinical Oncology 16 2825 2833
69. McLaughlin P. Grillo-Lopez A. Maloney D.G. 1998b Efficacy controls and long-term follow-up of patients treated with rituximab for relapsed or refractory low-grade or follicular NHL Blood 92 1712a
70. Milligan D.W. Ruiz de Elvira M.C. Kolb H.J. Goldstone A.H. Meloni G. Rohatiner A.Z. Colombat P. Schmitz N. 1999 Secondary leukemia and myelodyplasia after autografting for lymphoma: results from the EBMT. EMT Lymphoma and Late Effects Working Parties. European Group for Blood and Marrow Transplantation British Journal of Haematology 106 1020 1026
71. Mills W. Chopra R. McMillan A. Pearce R. Linch D.C. Goldstone A.H. 1995 BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma Journal of Clinical Oncology 13 588 595
72. Milpied N. Fielding A.K. Pearce R.M. Ernst P. Goldstone A.H. 1996 Allogeneic bone marrow transplantation is not better than autologous transplant for patients with relapsed Hodgkin's disease Journal of Clinical Oncology 14 1291 1296
73. Mollee P. Lazarus H.M. Lipton J. 2003 Why aren't we performing more allografts for aggressive non-Hodgkin's lymphoma Bone Marrow Transplantation 31 953 960
74. Montoto S. Lopez-Guillermo A. Altes A. Perea G. Ferrer A. Camos M. Villela L. Bosch F. Esteve J. Cervantes F. Blade J. Nomdedeu B. Campo E. Sierra J. Monserrat E. 2004 Predictive value of follicular lymphoma international prognostic index (FLIPI) in patients with follicular lymphoma at first progression Annals of Oncology 15 1484 1489
75. Morris E. Thomson K. Craddock C. Mahendra P. Milligan D. Cook G. Smith G. Parker A. Schey S. Chopra R. Hatton C. Tighe J. Hunter A. Peggs K. Linch D. Goldstone A. Mackinnon S. 2004 Outcome following alemtuzumab-containing reduced intensity allogeneic transplant regimen for relapsed and refractory non-Hodgkin's lymphoma (NHL) Blood 104 3865 3871
76. Morschhauser F. Huglo D. Martinelli G. Paganelli G. Zinzani P. Hadijiyiannakis D. Liberati A. Illidge T. Milpied N. Kalmus J. Morel P. Reimann U. Marcus R. 2005 Yttrium-90 Ibritumomab Tiuxetan (Zevalin) induces high response rates in previously treated patients with diffuse large B cell lymphoma (DLBCL) Annals of Oncology 16 Suppl. 5 abstract 65, v54
77. Moskowitz C.H. Bertino J.R. Glassman J.R. Hedrick E.E. Hunte S. Coady-Lyons N. Agus D. Goy A. Jurcic J. Noy A. O'Brian J. Portlock C. Straus D. Childs B. Frank R. Yahalom J. Filippa D. Louie D. Nimer S. Zelenetz A.D. 1999 Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma Journal of Clinical Oncology 17 3776 3785
78. Moskowitz C.H. Nimer S.D. Zelenetz A.D. Trippett T. Hedrick E.E. Filippa D.A. Louie D. Gonzales M. Walits J. Coady-Lyons N. Qin J. Frank R. Bertino J.R. Goy A. Noy A. O'Brian J.P. Straus D. Portlock C.S. Yahalom J. 2001 A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin's disease: analysis by intent to treat and development of a prognostic model Blood 3 616 623
79. Peggs K.S. Hunter A. Chopra R. Parker A. Mahendra P. Milligan D. Craddock C. Pettengell R. Dogan A. Thomson K.J. Morris E.C. Hale G. Waldmann H. Goldstone A. Linch D.C. Mackinnon S. 2005 Clinical evidence of graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation Lancet 365 1934 1941
80. Peterson B.A. Petroni G.R. Frizzera G. Barcos M. Bloomfield C.D. Nissen N.I. Hurd D.D. Henderson E.S. Sartiano G.P. Johnson J.L. Holland J.F. Gottlieb A.J. 2003 Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group British Journal of Clinical Oncology 21 5 15
81. Pfreundschuh M.G. Rueffer U. Lathan B. Schmitz N. Brosteneau O. Hasenclever D. Haas R. Kirchner H. Koch P. Kuse R. 1994 Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin's Disease Study Group Journal of Clinical Oncology 12 580 586
82. Pfreundschuh M. Truemper L. Kloess M. Schmits R. Feller A.C. Rübe C. Rudolph C. Reiser M. Hossfeld D. Eimermacher H. Hasenclever D. Schmitz N. Loeffler M. 2004a Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL Blood 104 634 641
83. Pfreundschuh M.G. Trümper L. Ma D. Österborg A. Pettengell R. Trneny M. Shephard L. Walewski J. Zinzani P.L. Loeffler M. 2004b Randomized intergroup trial of first line treatment for patients < Combining double low line 60 years with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) with a CHOP-like regimen with and without the anti-CD20 antibody rituximab - early stopping after the first interim analysis Proceedings of the American Society of Clinical Oncology 23 556 Abstract 6500, 556
84. Philip T. Guglielmi C. Hagenbeek A. Somers R. Van der Lelie H. Bron D. Sonneveld P. Gisselbrecht B. Cahn J.Y. Harrousseau J.L. Coiffier B. Biron P. Mandelli F. Chauvin F. 1995 Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive Non-Hodgkin's Lymphoma New England Journal of Medicine 333 1540 1545
85. Phillips G.L. Reece D.E. Barnett M.J. 1989 Allogeneic marrow transplantation for refractory Hodgkin's disease Journal of Clinical Oncology 7 1039 1045
86. Prince H. Imrie K. Crump M. 1996 The role of intensive therapy and autologos blood and marrow transplantation for chemotherapy-sensitive relapsed and primary refractory non-Hodgkin's lymphoma: identification of major prognostic groups British Journal of Haematology 92 880 889
87. Ratanatharathorn V. Uberti J. Karanes C. Abella E. Lum L. 1994 Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma Blood 84 1050 1055
88. Reece D.E. Connors J.M. Spinelli J.J. 1994 Intensive therapy with cyclophosphamide, carmustine, etoposide ± cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy Blood 83 1193 1199
89. Robinson P.R. Goldstone A.H. Mackinnon S. Carella A. Russell N. Ruiz de Elvira C. Taghipour G. Schmitz N. 2002 Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation Blood 100 4310 4316
90. Rodriguez M.A. Cabanillas F.C. Velasquez W. Hagemeister F.B. McLaughlin P. Swan F. Romaguera J.E. 1995 Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP Journal of Clinical Oncology 13 1734 1740
91. Rodriguez J. Rodriguez M.A. Fayad L. McLaughlin P. Swan F. Sarris A. Romaguera J. Andersson B. Cabanillas F. Hagemeister F.B. 1999 ASHAP: a regimen for cytoreduction of refractory or recurrent Hodgkin's disease Blood 11 3632 3636
92. Rodriguez-Monge E. Cabanillas F. 1997 Long-term follow-up of platinum-based lymphoma salvage regimens. The M.D. Anderson Cancer Center experience Hematology/Oncology Clinics of North America 11 937 947
93. Rohatiner A.Z. Johnson P.W. Price C.G. 1994 Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma Journal of Clinical Oncology 12 1177 1184
94. Santini G. Nati S. Spriano M. Gallamini A. Pierluigi D. Congui A.M. 2001 Fludarabine in combination with cyclophosphamide or with cyclophosphamide plus mitoxantrone for relapsed or refractory low-grade non-Hodgkin's lymphoma Haematologica 86 282 286
95. Santoro A. Bredenfeld H. Devizzi L. 2000 Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study Journal of Clinical Oncology 18 2615 2619
96. Schmitz N. Pfistner B. Sextro M. Sieber M. Carella A.M. Haenel M. Boissevain F. Zschaber R. Muller P. Kirchner H. Lohni A. Decker S. Koch B. Hasenclever D. Diehl V. 2002 Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial Lancet 359 2065 2071
97. Schmitz N. Haverkamp H. Josting A. Carella A.M. Haenel M. Boissevain F. Zschaber R. Hasenclever D. Diehl V. 2004a Long-term results of HD-R1: conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoetic stem cell transplantation in relapsed Hodgkin's disease European Journal of Hematology 73 Suppl. 65 R16
98. Schmitz N. Sureda A. Robinson S. 2004b Allogeneic transplantation of hematopoietic stem cells after nonmyeloablative conditioning for Hodgkin's disease: indications and results Seminars in Oncology 31 27 32
99. Schmitz N. Kloess M. Engert A. Berdel W. Metzner B. Truemper L. Loeffler M. Pfreundschuh M. Glass B. 2005 Dose-escalated CHOP plus etoposide (MegaCHOEP) followed by repeated transplantation of autologous peripheral blood stem cells in younger patients with aggressive NHL. A series of phase II studies by the German High-Grade NHL Study Group Annals of Oncology 16 Suppl. 5 67:v54
100. Schouten H.C. Biermann P.J. Vaughan W.P. Kessinger A. Vose J.M. Weisenburger D.D. Armitage J.O. 1989 Autologous bone marrow transplantation in follicular non-Hodgkin's lymphoma before and after histologic transformation Blood 74 2579 2584
101. Schouten H.C. Qian W. Kvaloy S. Porcellini A. Hagberg H. Johnsen H.E. Doorduijn J.K. Sydes M.R. Kvalheim G. 2003 High dose therapy improves progression free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial Journal of Clinical Oncology 21 3918 3927
102. Seyfarth B. Kuse R. Sonnen R. Glass B. Schmitz N. Dreger P. 2001 Autologous stem cell transplantation for follicular lymphoma: no benefit for early transplant Annals of Hematology 80 398 405
103. Seymour J.F. Grigg A.P. Szer J. Fox R.M. 2001 Fludarabine and mitoxantrone: effective and well-tolerated salvage therapy in relapsed indolent lymphoproliferative disorders Annals of Oncology 12 1455 1460
104. Solal-Celigny P. Roy P. Colombat P. White J. Armitage J. Montserrat E. 2004 Follicular Lymphoma International Prognostic Index Blood 104 1258 1265
105. Spaepen K. Stroobants S. Dupont P. Vandenberghe P. Maertens J. Bormans G. Thomas J. Balzarini J. De Wolf-Peeters C. Mortelmans L. Verhoef G. 2003 Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluordeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation Blood 102 53 59
106. Sureda A. Robinson S. Ruiz de Elvira C. 2003 Non myeloablative allogeneic stem cell transplantation reduces transplant related mortality in comparison with conventional allogeneic transplantation in relapsed or refractory Hodgkin's disease: results of the European Group for Blood and Marrow Transplantation Blood 102 Suppl. 1 1461 (abstr.) 692
107. Tobinai K. Kobayashi Y. Narabayashi M. 1998 Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) rituximab in relapsed B-cell lymphoma Annals of Oncology 9 527 534
108. Van Besien K. Sobocinski K. Rowlings P.A. 1998 Allogeneic bone marrow transplantation for low-grade lymphoma Blood 92 832 1836
109. Van Besien K. Loberiza F.R. Bajorunaite R. 2003 Comparison of autologous and allogeneic hematopoetic stem cell transplantation for follicular lymphoma Blood 102 3521 3529
110. Velasquez W.S. Cabanillas F. Salvador P. McLaughlin P. Fridrik M. Tucker S. 1988 Effective salvage therapy for lymphoma with cisplatin in combination with high-dose ara-C and dexamethasone (DHAP) Blood 71 117 122
111. Velasquez W.S. McLaughlin P. Tucker S. Hagemeister F.B. Swan F. Rodriguez M.A. 1994 ESHAP - an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study Journal of Clinical Oncology 12 1169 7116
112. Weide R. Heymanns J. Gores A. Köppler H. 2002 Bendamustine, mitoxantrone and rituximab (BMR): a new effective regimen for refractory or relapsed indolent lymphomas Leukemia & Lymphoma 43 327 331
113. Weide R. Koeppler H. Heymanns J. Thomalla J. Hess G. Gamm H. Aldaoud A. Schmitz S. Haak U. Plewe D. Burkhard O. Gaede B. Hinrichs F. Pflueger K.H. Dreyling M. Unterhalt M. Hiddemann W. 2004 Bendamustine/mitoxantrone/rituximab (BMR): a very effective and well tolerated immuno-chemotherapy for relapsed and refractory indolent lymphomas - results of a multicentre phase-II study of the German Low Grade Lymphoma Study Group (GLSG) Blood 104 681a Abstract 695-II
114. Wilson W.H. Bryant G. Bates S. Fojo A. Wittes R.E. Steinberg S.M. Kohler D.R. Jaffe E.S. Herdt J. Cheson B.D. 1993 EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma Journal of Clinical Oncology 11 1573 1582
115. Winter J.N. Inwards D. Erwin W. Wiseman G. Rademaker A.W. Patton D. 2002 Zevalin dose-escalation followed by high-dose BEAM and autologous peripheral blood progenitor cell (PBPC) transplantation in non-Hodgkin's lymphoma: early outcome results Blood 100 411a
116. Witzig T.E. Gordon L. Cabanillas F. Czuczman M. Emmanouilides C. Joyce R. Pohlman B. Bartlett N. Wiseman G. Padre N. Grillo-Lopez A. Mltani P. White C. 2002a Randomized controlled trial of Yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell Non-Hodgkin's lymphoma Journal of Clinical Oncology 20 2453 2463
117. Witzig T.E. Flinn I. Gordon L. 2002b Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular Non-Hodgkin's lymphoma Journal of Clinical Oncology 20 3262 3269
118. Witzig T.E. Emmanouilides C. Molina A. 2003 Yttrium-90 ibritumomab tiuxetan radioimmunotherapy (RIT) induces durable complete responses (CR/Cru) in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) Proceedings of the American Society of Clinical Oncology 22 abstract 2400, 597
119. Young R.C. Longo D.L. Glatstein E. 1988 The treatment of indolent lymphomas: watchful waiting versus aggressive combined modality treatment Seminars in Hematology 25 11 16